Ivosidenib vs Olutasidenib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: Mutant IDH1 · full Acute Myeloid Leukemia pipeline
Ivosidenib · Tibsovo
Marketed by Servier and partners
NCT03173248 · Phase 3 · active, not recruiting
Participants were randomly assigned 1:1 and participants, care providers and investigators were masked, with a placebo plus azacitidine comparator. The study enrolled 146 people, which is modest, but the primary endpoint, event-free survival, favored ivosidenib with a hazard ratio of 0.33 (95% CI 0.16 to 0.69, p=0.0011), so it was met.
Next expected readout: December 2026 · NCT02074839 (registry estimate)
Reported efficacy
Event-Free Survival (EFS) (Up to Week 24): Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis) (met)
Result source: NCT03173248
Olutasidenib
Marketed by Rigel Pharmaceuticals and partners
NCT02719574 · Phase 1/2 · completed
This is a single-arm, open-label study with no randomization, no blinding, and no comparator or control arm, and it is not an extension of a prior randomized trial. All enrolled patients received olutasidenib (alone or with azacitidine/cytarabine), and the Phase 2 primary endpoints are descriptive response/remission rates rather than comparisons against a control. Because there is no control group, the results cannot separate drug effect from natural history or patient selection, so the evidence is weak regardless of the reported response rates.
Next expected readout: January 2027 · NCT07411586 (registry estimate)
Reported efficacy
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)); Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values (Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)); Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG) (Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)); Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria (Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)); Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria (Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)); Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria (Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)); Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate (Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)): Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)): Phase 1: FT-2102 (Single Agent) — TEAEs: 16 Participants; SAEs: 10 Participants | Phase 1: Total FT-2102 (Single Agent) — TEAEs: 31 Participants; SAEs: 23 Participants | Phase 1: FT-2102 + Azacitidine (Combination Therapy) — TEAEs: 39 Participants; SAEs: 30 Participants | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) — TEAEs: 46 Participants; SAEs: 36 Participants (not_applicable)
Result source: NCT02719574
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ivosidenib | Olutasidenib |
|---|---|---|
| OS, median | —Trial running · NCT03013998 | 11.6bNCT027195746 other results
|
| Complete remission | —Trial running · NCT03013998 | —Not reported |
| Event-free survival, median | 0.0 vs 0.0±0 vs placeboNCT03173248 | 5.5bNCT027195747 other results
|
| Duration of response, median | —Trial running · NCT03013998 | 14.8bNCT027195747 other results
|
OS, median
- Ivosidenib
- —Trial running · NCT03013998
- Olutasidenib
- 11.6bNCT02719574
6 other results
- 25.2 NCT02719574
- 11.6 NCT02719574
- 10.2 NCT02719574
- 1.2 NCT02719574
- 14 NCT02719574
- 18.7 NCT02719574
Complete remission
- Ivosidenib
- —Trial running · NCT03013998
- Olutasidenib
- —Not reported
Event-free survival, median
- Ivosidenib
- 0.0 vs 0.0±0 vs placeboNCT03173248
- Olutasidenib
- 5.5bNCT02719574
7 other results
- 18.4 NCT02719574
- 5.7 NCT02719574
- 7.8 NCT02719574
- 4.8 NCT02719574
- 1.1 NCT02719574
- 5.5 NCT02719574
- 8.1 NCT02719574
Duration of response, median
- Ivosidenib
- —Trial running · NCT03013998
- Olutasidenib
- 14.8bNCT02719574
7 other results
- 22 NCT02719574
- 3.6 NCT02719574
- 20 NCT02719574
- 7.3 NCT02719574
- 4.7 NCT02719574
- 10.6 NCT02719574
- 20.9 NCT02719574
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ivosidenib: 2 of 4 rows · Olutasidenib: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ivosidenib | Olutasidenib |
|---|---|---|
| Dropout rate | n/a: no completion milestone NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 | —Phase 1: FT-2102 (Single Agent)a NCT02719574 · Phase 1/2 show 9 more results—Phase 1: FT-2102 + Azacitidine (Co NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 1; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 2; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 3; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 4; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 5; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 6; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 7; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 8; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination |
| Discontinued due to AEs | — NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 | —Phase 1: FT-2102 (Single Agent)a NCT02719574 · Phase 1/2 show 9 more results—Phase 1: FT-2102 + Azacitidine (Co NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 1; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 2; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 3; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 4; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 5; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 6; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination —Phase 2: Cohort 7; FT-2102 (Single NCT02719574 · Phase 1/2 —Phase 2: Cohort 8; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination |
| Serious AEs | 69% NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 | 62.5%Phase 1: FT-2102 (Single Agent)a NCT02719574 · Phase 1/2 show 9 more results76.9%Phase 1: FT-2102 + Azacitidine (Co NCT02719574 · Phase 1/2 · combination 75.2%Phase 2: Cohort 1; FT-2102 (Single NCT02719574 · Phase 1/2 33.3%Phase 2: Cohort 2; FT-2102 (Single NCT02719574 · Phase 1/2 80%Phase 2: Cohort 3; FT-2102 (Single NCT02719574 · Phase 1/2 60%Phase 2: Cohort 4; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination 85.7%Phase 2: Cohort 5; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination 65%Phase 2: Cohort 6; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination 80%Phase 2: Cohort 7; FT-2102 (Single NCT02719574 · Phase 1/2 81.8%Phase 2: Cohort 8; FT-2102 + Azaci NCT02719574 · Phase 1/2 · combination |
| Most frequent reported AEs | nausea 42.3% (placebo 38.4%) vomiting 39.4% (placebo 26%) diarrhoea 35.2% (placebo 34.2%) NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 | show 9 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ivosidenib
Olutasidenib
show 6 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivosidenib's landscape · Olutasidenib's landscape